Publicacions en col·laboració amb investigadors/es de Radboud University Nijmegen Medical Centre (80)

2024

  1. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732

  2. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Report on palliative sedation medication usage: a survey of palliative care experts in Eight European countries

    BMC Palliative Care, Vol. 23, Núm. 1

  4. Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation: An international Delphi study

    Palliative Medicine, Vol. 38, Núm. 2, pp. 213-228

  5. Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines

    Breast, Vol. 78

  6. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. Blue Light Exposure: Ocular Hazards and Prevention—A Narrative Review

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 755-788

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

  5. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    EJNMMI Radiopharmacy and Chemistry, Vol. 8, Núm. 1

  6. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  7. Monitoring the clinical practice of palliative sedation (PALSED) in patients with advanced cancer: an international, multicentre, non-experimental prospective observational study protocol

    BMC Palliative Care, Vol. 22, Núm. 1

  8. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi

    Molecular Therapy Nucleic Acids, Vol. 34

  9. Regulations on palliative sedation: an international survey across eight European countries

    European journal of public health, Vol. 33, Núm. 1, pp. 35-41

2022

  1. Association of obesity with 3-month mortality in kidney failure patients with COVID-19

    Clinical Kidney Journal, Vol. 15, Núm. 7, pp. 1348-1360

  2. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months after a Diagnosis of COVID-19

    Transplantation, Vol. 106, Núm. 5, pp. 1012-1023

  3. Consensus Statement on Bone Conduction Devices and Active Middle Ear Implants in Conductive and Mixed Hearing Loss

    Otology and Neurotology, Vol. 43, Núm. 5, pp. 513-529

  4. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  5. Pregnancy in cystinosis patients with chronic kidney disease: A European case series

    Journal of Inherited Metabolic Disease, Vol. 45, Núm. 5, pp. 963-968